AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
Astrazeneca Plc $AZN Shares Purchased by Bamco Inc. NY
Bamco Inc. NY increased its holdings in Astrazeneca Plc (NYSE: AZN) by 9.4% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 140,008 shares of the company's stock after acquiring an additional 12,000 shares during the period. Bamco Inc. NY's holdings in Astrazeneca were worth $10,741,000
Ameriprise Financial Inc. Boosts Stock Position in Astrazeneca Plc $AZN
Ameriprise Financial Inc. boosted its stake in shares of Astrazeneca Plc (NYSE: AZN) by 13.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,707,561 shares of the company's stock after acquiring an additional 660,569 shares during the quarter. Ameriprise Financial Inc.
AstraZeneca's Imfinzi Gets EU Approval for Treatment of Early Gastric Cancer
Imfinzi is approved in the EU to treat early-stage gastric and gastroesophageal cancers in combination with chemotherapy.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceutical company, from 15,000p to 18,000p, reiterating a 'buy' recommendation, arguing that the drugmaker is better positioned for long-term growth than the market appreciates. The broker's analysts have reversed their cautious stance on AVANZAR, a phase III clinical trial testing AZ's cancer drug Datroway (datopotamab deruxtecan) combined with immunotherapy Imfinzi and chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff
The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and immune engagers, according to UBS, driving an increase to its price target and reiterated 'buy' rating. Analyst Matthew Weston said the company and the wider sector face a "significant patent cliff" around 2030-and-beyond but argues the FTSE 100 drugmaker is well positioned to manage this with "sector leading replacement power".
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Shore Capital downgrades AstraZeneca as R&D spending dampens earnings trajectory
Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', citing a less favourable earnings trajectory as the drugmaker prioritises revenue growth through escalating research spending. The broker warns the current valuation looks full at 20 times forecast 2026 earnings despite confidence the company can exceed its $80 billion 2030 revenue target.
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.
Citi maintains 'buy' on AstraZeneca with £170 target, cites sector-best pipeline
Double-digit earnings outlook and strong trial momentum support top pick status AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) remains a top pick at Citi following full-year results and 2026 guidance that the bank described as “reassuring”, with a reiterated target price of £170 and unchanged earnings forecasts. Management confirmed expectations for low double-digit earnings growth in 2026, aligning with consensus, while the medium single- to high single-digit revenue outlook was ahead of market forecasts.
